Cytosorbents Corp - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS

Ticker Exchange SIC # Website Latest Ticker
CTSO Nasdaq 3845 http://cytosorbents.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cytosorbents Corp

CytoSorbents Highlights New Clinical Data from Current Studies at the Live 42nd International Symposium on Intensive Care & Emergency Medicine (ISICEM) - Mar 22nd, 2023 12:09 pm
Investors in Cytosorbents (NASDAQ:CTSO) have unfortunately lost 57% over the last five years - Mar 20th, 2023 11:38 am
CTSO: UPDATE: CytoSorbents reports 4th quarter and fiscal 2022 financial and operating results which showed positive revenue growth on a Core Product constant currency basis. - Mar 17th, 2023 1:10 pm
CytoSorbents Comments on Bank Exposure and Diversified Cash Position - Mar 14th, 2023 11:00 am
Cytosorbents Corporation (NASDAQ:CTSO) Q4 2022 Earnings Call Transcript - Mar 13th, 2023 6:53 am
Q4 2022 Cytosorbents Corp Earnings Call - Mar 10th, 2023 3:33 pm
CytoSorbents Reports Fourth Quarter and Full Year 2022 Results - Mar 9th, 2023 9:15 pm
New European “Guidelines for the Management of Severe Perioperative Bleeding” Consider Hemoadsorption for the First-Time - Mar 7th, 2023 12:00 pm
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference - Feb 27th, 2023 12:00 pm
CytoSorbents to Report Fiscal 2022 Operating and Financial Results - Feb 24th, 2023 12:00 pm
Quite a few insiders invested in Cytosorbents Corporation (NASDAQ:CTSO) last year which is positive news for shareholders - Feb 21st, 2023 11:22 am
CTSO: INITIATION: Established medical device company with advanced proprietary blood purification technologies positioned for rapid profitable growth going forward. - Feb 15th, 2023 1:20 pm
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue - Jan 31st, 2023 12:15 pm
Cytosorbents Corporation's (NASDAQ:CTSO) market cap touched US$103m last week, benefiting both individual investors who own 52% as well as institutions - Jan 29th, 2023 2:58 pm
CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial - Jan 23rd, 2023 12:00 pm
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs - Jan 17th, 2023 12:00 pm
Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth? - Jan 12th, 2023 12:16 pm
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement - Dec 29th, 2022 12:00 pm
CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications - Dec 21st, 2022 12:00 pm
These Analysts Think Cytosorbents Corporation's (NASDAQ:CTSO) Sales Are Under Threat - Nov 17th, 2022 10:21 am